About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Inclisiran

Company: Novartis Pharmaceuticals
Mechanism: Mechanism not yet reported
Route: Route not yet reported
Recruiting trials: 22 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

22 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 17, 2026

Trial details

Recruiting NCT NCT05682378

Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies

Not yet reported Novartis Pharmaceuticals 195 participants Est. completion 2032-03-28 52 sites Stand-alone

Other conditions: Heterozygous or Homozygous Familial Hypercholesterolemia
View official trial listing →
Recruiting NCT NCT06126367

Assessment of Lipoprotein(a) and Endogenous Fibrinolysis in Atherosclerotic Cardiovascular Disease/Aortic Valve Disease

East and North Hertfordshire NHS Trust 180 participants Est. completion 2027-10-01 1 site

Other conditions: Atherosclerosis, Aortic Valve Disease
View official trial listing →
Recruiting NCT NCT06287177

Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Inclisiran in Italy

Federico II University 3000 participants Est. completion 2030-11-01 1 site

Other conditions: Hypercholesterolemia
View official trial listing →
Recruiting NCT NCT06338293

Effects of Inclisiran Combined With Statins on the Morphology of Coronary Vulnerable Plaques

Not yet reported Nanjing First Hospital, Nanjing Medical University 40 participants Est. completion 2025-12-31 1 site Stand-alone

Cardiovascular disease
View official trial listing →
Recruiting NCT NCT06494501

The Prevent Coronary Artery Disease Trial

Not yet reported Icahn School of Medicine at Mount Sinai 1600 participants Est. completion 2032-06-30 1 site Stand-alone

Cardiovascular disease
View official trial listing →
Recruiting NCT NCT06501443

LATAM LOWERS LDL-C

Not yet reported Novartis Pharmaceuticals 520 participants Est. completion 2026-11-29 11 sites Stand-alone

Other conditions: Hypercholesterolaemia
View official trial listing →
Recruiting NCT NCT06597006

Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

Not yet reported Novartis Pharmaceuticals 9 participants Est. completion 2029-04-15 19 sites Stand-alone

Other conditions: Familial Hypercholesterolemia - Homozygous
View official trial listing →
Recruiting NCT NCT06597019

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

Not yet reported Novartis Pharmaceuticals 60 participants Est. completion 2029-04-15 66 sites Stand-alone

Other conditions: Familial Hypercholesterolemia - Heterozygous
View official trial listing →
Recruiting NCT NCT06738758

Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients(ELITE-ACS)

Yun Dai Chen 6000 participants Est. completion 2027-12-31 1 site

Other conditions: Acute Coronary Syndromes
View official trial listing →
Recruiting NCT NCT06770543

Leqvio rPMS (Regulatory Post-Marketing Surveillance in Korea)

Novartis Pharmaceuticals 1500 participants Est. completion 2031-01-02 4 sites

Other conditions: Primary Hypercholesterolemia or Mixed Dyslipidemia
View official trial listing →
Recruiting NCT NCT06813911

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

Not yet reported Novartis Pharmaceuticals 340 participants Est. completion 2028-02-29 95 sites

Cardiovascular disease
View official trial listing →
Recruiting NCT NCT06858332

Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia

Novartis Pharmaceuticals 2382 participants Est. completion 2027-09-30 20 sites

Cardiovascular disease
View official trial listing →
Recruiting NCT NCT06865885

LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering

Not yet reported University of California, San Diego 100 participants Est. completion 2027-03-31 1 site

Metabolic syndrome Other conditions: Drug Interactions, Primary Prevention, LDL-Cholersterol Lowering
View official trial listing →
Recruiting NCT NCT06909565

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

Not yet reported Duke University 6000 participants Est. completion 2029-12 138 sites

Other conditions: Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
View official trial listing →
Recruiting NCT NCT07102628

Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes

Not yet reported Novartis Pharmaceuticals 300 participants Est. completion 2027-02-11 69 sites Stand-alone

Other conditions: Acute Coronary Syndrome
View official trial listing →
Recruiting NCT NCT07142265

Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients

Novartis Pharmaceuticals 300 participants Est. completion 2027-09-30 18 sites

Cardiovascular disease
View official trial listing →
Recruiting NCT NCT07543731

A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab

Novartis Pharmaceuticals 5995 participants Est. completion 2026-10-30 1 site

Cardiovascular disease Other conditions: Hypercholesterolemia, Familial
View official trial listing →
Recruiting NCT NCT07581808

Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention

Not yet reported University Medical Centre Ljubljana 60 participants Est. completion 2027-06 1 site Stand-alone

Cardiovascular disease Other conditions: Hypercholesterolemia
View official trial listing →
Recruiting NCT NCT07610278

A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia

Not yet reported Novartis Pharmaceuticals 120 participants Est. completion 2028-02-03 29 sites Stand-alone

Other conditions: Hypercholesterolaemia
View official trial listing →
Recruiting NCT NCT07626281

Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation

Not yet reported Novartis Pharmaceuticals 120 participants Est. completion 2026-12-21 3 sites Stand-alone

Other conditions: Inclisiran Formulation
View official trial listing →
Recruiting NCT NCT07704918

Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma

Not yet reported University of Colorado, Denver 40 participants Est. completion 2028-12 1 site Stand-alone

Other conditions: Melanoma
View official trial listing →
Recruiting NCT NCT07803822

Phase 2 Clinical Study of MWX203 Injection Alone or in Combination With Inclisiran Sodium Injection in Patients With Mixed Dyslipidemia

Not yet reported Shanghai Minwei Biotechnology Co., Ltd 216 participants Est. completion 2028-02 1 site Stand-alone

Other conditions: Mixed Dyslipidemia
View official trial listing →
Completed NCT NCT02314442

A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)

Not yet reported Alnylam Pharmaceuticals 70 participants Est. completion 2015-11 2 sites

Other conditions: Hypercholesterolemia
View official trial listing →
Completed NCT NCT02597127

Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)

Not yet reported The Medicines Company 501 participants Est. completion 2017-06-07 54 sites

Cardiovascular disease Other conditions: Familial Hypercholesterolemia, Diabetes
View official trial listing →
Completed NCT NCT02963311

A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

Not yet reported The Medicines Company 9 participants Est. completion 2018-10-08 3 sites

Other conditions: Homozygous Familial Hypercholesterolemia
View official trial listing →
Completed NCT NCT03060577

An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol

Not yet reported Novartis Pharmaceuticals 382 participants Est. completion 2021-12-17 52 sites Stand-alone

Cardiovascular diseaseType 2 diabetes Other conditions: Symptomatic Atherosclerosis, Familial Hypercholesterolemia
View official trial listing →
Completed NCT NCT03159416

A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Function (ORION-7)

Not yet reported The Medicines Company 31 participants Est. completion 2018-03-24 2 sites Stand-alone

Other conditions: Renal Impairment
View official trial listing →
Completed NCT NCT03397121

Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)

Not yet reported The Medicines Company 482 participants Est. completion 2019-09-17 45 sites Stand-alone

Other conditions: Heterozygous Familial Hypercholesterolemia, Elevated Cholesterol
View official trial listing →
Completed NCT NCT03399370

Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

Not yet reported The Medicines Company 1561 participants Est. completion 2019-09-17 145 sites Stand-alone

Cardiovascular disease Other conditions: Elevated Cholesterol
View official trial listing →
Completed NCT NCT03400800

Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol

Not yet reported The Medicines Company 1617 participants Est. completion 2019-08-27 70 sites Stand-alone

Cardiovascular disease Other conditions: Risk Factor, Cardiovascular, Elevated Cholesterol
View official trial listing →
Active, not recruiting NCT NCT03705234

A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease

Not yet reported University of Oxford 16124 participants Est. completion 2049-12 2 sites Stand-alone

Cardiovascular disease
View official trial listing →
Completed NCT NCT03814187

Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C

Not yet reported Novartis Pharmaceuticals 3275 participants Est. completion 2023-02-13 238 sites Stand-alone

Cardiovascular disease Other conditions: Elevated Cholesterol, Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia
View official trial listing →
Completed NCT NCT03851705

A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

Not yet reported Novartis Pharmaceuticals 56 participants Est. completion 2021-09-09 13 sites Stand-alone

Other conditions: Homozygous Familial Hypercholesterolemia
View official trial listing →
Status unknown NCT NCT04073797

PET Imaging of Inflammation and Lipid Lowering Study

Not yet reported University of Cambridge 63 participants Est. completion 2026-03-01 1 site Stand-alone

Other conditions: Hypercholesterolemia, Hypercholesterolemia, Familial, Atherosclerosis, Carotid Artery Plaque
View official trial listing →
Completed NCT NCT04652726

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia

Not yet reported Novartis Pharmaceuticals 141 participants Est. completion 2024-11-27 59 sites Stand-alone

Other conditions: Familial Hypercholesterolemia - Heterozygous
View official trial listing →
Completed NCT NCT04659863

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia

Not yet reported Novartis Pharmaceuticals 13 participants Est. completion 2024-11-18 11 sites Stand-alone

Other conditions: Familial Hypercholesterolemia - Homozygous
View official trial listing →
Completed NCT NCT04666298

Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C

Not yet reported Novartis Pharmaceuticals 312 participants Est. completion 2022-10-19 42 sites Stand-alone

Other conditions: Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia
View official trial listing →
Active, not recruiting NCT NCT04765657

Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)

Not yet reported Novartis Pharmaceuticals 345 participants Est. completion 2026-12-28 45 sites Stand-alone

Other conditions: Hypercholesterolemia
View official trial listing →
Completed NCT NCT04774003

Study of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inclisiran in Chinese Participants With Elevated Serum LDL-C

Not yet reported Novartis Pharmaceuticals 40 participants Est. completion 2021-10-18 3 sites Stand-alone

Other conditions: Hyperlipidemia
View official trial listing →
Completed NCT NCT04807400

Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support

Not yet reported Novartis Pharmaceuticals 892 participants Est. completion 2023-01-13 17 sites Stand-alone

Cardiovascular disease Other conditions: Elevated Low Density Lipoprotein Cholesterol
View official trial listing →
Completed NCT NCT04873934

Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome

Not yet reported Novartis Pharmaceuticals 400 participants Est. completion 2024-08-07 88 sites Stand-alone

Other conditions: Acute Coronary Syndrome
View official trial listing →
Completed NCT NCT04929249

A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)

Not yet reported Novartis Pharmaceuticals 450 participants Est. completion 2023-09-15 43 sites Stand-alone

Cardiovascular disease
View official trial listing →
Completed NCT NCT05004675

Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients

Not yet reported LIB Therapeutics LLC 166 participants Est. completion 2024-10-15 7 sites

Other conditions: Hypercholesterolemia, Atherosclerotic Ischemic Disease
View official trial listing →
Active, not recruiting NCT NCT05030428

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Not yet reported Novartis Pharmaceuticals 17004 participants Est. completion 2027-05-10 983 sites Stand-alone

Cardiovascular disease
View official trial listing →
Completed NCT NCT05118230

Study to Assess the Real World Effectiveness of Inclisiran in Chinese Adult Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Novartis Pharmaceuticals 61 participants Est. completion 2024-07-20 2 sites

Other conditions: Primary Hypercholesterolemia, Mixed Dyslipidemia
View official trial listing →
Completed NCT NCT05192941

Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia

Not yet reported Novartis Pharmaceuticals 1770 participants Est. completion 2025-03-19 136 sites Stand-alone

Other conditions: Hypercholesterolemia
View official trial listing →
Active, not recruiting NCT NCT05360446

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

Not yet reported Novartis Pharmaceuticals 609 participants Est. completion 2026-10-26 89 sites Stand-alone

Cardiovascular disease
View official trial listing →
Completed NCT NCT05362903

A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting

Novartis Pharmaceuticals 1868 participants Est. completion 2025-11-28 121 sites

Other conditions: Hypercholesterolemia
View official trial listing →
Active, not recruiting NCT NCT05399992

Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD

Novartis Pharmaceuticals 847 participants Est. completion 2026-10-05 40 sites

Other conditions: Primary Hypercholesterolemia, Mixed Dyslipidemia
View official trial listing →
Status unknown NCT NCT05438069

German Inclisiran Network: Retrospective Registry of Patients Being Treated With the siRNA Inclisiran in Germany

Jena University Hospital 500 participants Est. completion 2025-12-11 1 site

Other conditions: Hypercholesterolemia
View official trial listing →
Not yet recruiting NCT NCT05587621

Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target)

Not yet reported Jena University Hospital 300 participants Est. completion 2026-12-31 10 sites

Cardiovascular disease Other conditions: LDL-cholesterol
View official trial listing →
Status unknown NCT NCT05639218

Impact of Optimal Pharmacotherapy on Lipid Profile and Qualitative Features of Atherosclerotic Plaques

Pauls Stradins Clinical University Hospital 50 participants Est. completion 2023-12 1 site

Cardiovascular disease
View official trial listing →
Active, not recruiting NCT NCT05726838

The Belgian REAL (BE.REAL) Registry

Novartis Pharmaceuticals 600 participants Est. completion 2029-03-30

Cardiovascular disease
View official trial listing →
Active, not recruiting NCT NCT05739383

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Not yet reported Novartis Pharmaceuticals 14012 participants Est. completion 2029-04-16 983 sites Stand-alone

Cardiovascular disease
View official trial listing →
Completed NCT NCT05763875

Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.

Not yet reported Novartis Pharmaceuticals 350 participants Est. completion 2024-06-20 42 sites Stand-alone

Other conditions: Hypercholesterolemia
View official trial listing →
Terminated NCT NCT05834673

VICTORION-ASCERTAIN: Implementation Study (v-ASCERTAIN)

Not yet reported Monash University 6 participants Est. completion 2024-12-19 1 site

Cardiovascular disease Other conditions: Coronary Heart Disease (CHD), Cerebrovascular Disease, Peripheral Arterial Disease (PAD)
View official trial listing →
Completed NCT NCT05870657

Adherence and Persistence to Inclisiran Among Early Users in Germany

Novartis Pharmaceuticals 1109 participants Est. completion 2022-05-12 1 site

Other conditions: High Levels of Low-density Lipoprotein Cholesterol
View official trial listing →
Completed NCT NCT05888103

Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.

Not yet reported Novartis Pharmaceuticals 207 participants Est. completion 2024-10-24 28 sites Stand-alone

Other conditions: Primary Hypercholesterolemia or Mixed Dyslipidemia
View official trial listing →
Completed NCT NCT05974345

In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease

Novartis Pharmaceuticals 204691 participants Est. completion 2023-12-15 1 site

Cardiovascular disease
View official trial listing →
Active, not recruiting NCT NCT06249165

VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease

Not yet reported Duke University 130 participants Est. completion 2027-02-28 23 sites Stand-alone

Cardiovascular disease
View official trial listing →
Active, not recruiting NCT NCT06275724

Specified Drug-use Survey of Leqvio for s.c. Injection.

Novartis Pharmaceuticals 585 participants Est. completion 2026-12-17 107 sites

Other conditions: Familial Hypercholesterolaemia, Hypercholesterolaemia
View official trial listing →
Withdrawn NCT NCT06280976

Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)

Not yet reported University of Louisville Est. completion 2025-01-01 1 site Stand-alone

Cardiovascular disease Other conditions: Atherosclerosis, Heart Attack
View official trial listing →
Active, not recruiting NCT NCT06372925

Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction

Not yet reported Novartis Pharmaceuticals 318 participants Est. completion 2027-01-26 19 sites Stand-alone

Other conditions: Plaque, Atherosclerotic
View official trial listing →
Completed NCT NCT06386419

A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Not yet reported Novartis Pharmaceuticals 65 participants Est. completion 2026-01-13 9 sites Stand-alone

Other conditions: Primary Hypercholesterolemia, Mixed Dyslipidemia
View official trial listing →
Not yet recruiting NCT NCT06421363

Continuity of Care Between Primary Care Cardiology and Specialty Services for Patients With Chronic Ischemic Heart Disease

Not yet reported Jose Seijas Amigo 50 participants Est. completion 2027-08-01 6 sites Stand-alone

Other conditions: Ischemic Heart Disease, Acute Coronary Syndrome
View official trial listing →
Completed NCT NCT06431763

A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.

Not yet reported Novartis Pharmaceuticals 402 participants Est. completion 2026-01-02 55 sites Stand-alone

Other conditions: Hypercholesterolemia
View official trial listing →
Completed NCT NCT06507852

A Real-world Study of Inclisiran Adherence, Treatment Patterns, Patient Characteristics, and Effectiveness in ASCVD Patients With Hypercholesterolemia, ASCVD-risk Equivalent Patients With Hypercholesterolemia and Familial Hypercholesterolemia

Novartis 95 participants Est. completion 2023-07-06 1 site

Cardiovascular disease Other conditions: Hypercholesterolemia
View official trial listing →
Not yet recruiting NCT NCT06586684

Effect of Small Interfering RNA Inclisiran on Carotid Plaques As Assessed by Carotid Ultrasound

Not yet reported First Affiliated Hospital of Xinjiang Medical University 40 participants Est. completion 2026-09-30 Stand-alone

Other conditions: Carotid Plaque, Hyperlipidemia, Echocardiography
View official trial listing →
Completed NCT NCT06595069

A Real-world Study to Assess the Characteristics and Long-term Effectiveness of Inclisiran in Chinese Adult Patients

Novartis 600 participants Est. completion 2024-07-10 1 site

Other conditions: Hypercholesterolemia
View official trial listing →
Not yet recruiting NCT NCT06791031

PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in Acute Coronary Syndromes (REPRESS)

Not yet reported West China Hospital 212 participants Est. completion 2028-06 Stand-alone

Cardiovascular disease
View official trial listing →
Active, not recruiting NCT NCT06941792

Inclisiran Effectiveness in China: a Pragmatic Randomized Trial

Not yet reported Novartis Pharmaceuticals 1590 participants Est. completion 2027-04-30 19 sites Stand-alone

Other conditions: Coronary Heart Disease
View official trial listing →
Active, not recruiting NCT NCT06958315

Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study

Novartis Pharmaceuticals 219 participants Est. completion 2027-05-01 20 sites

Other conditions: Atherosclerotic Vascular Disease, Heterozygous Familial Hypercholesterolemia
View official trial listing →
Completed NCT NCT07023445

Patterns of Inclisiran Use in the Real World: An Analysis of US Databases

Novartis Pharmaceuticals 37688 participants Est. completion 2024-06-28 1 site

Cardiovascular disease Other conditions: Familial Hypercholesterolemia
View official trial listing →
Completed NCT NCT07214857

Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States

Novartis Pharmaceuticals 1385 participants Est. completion 2024-10-09 1 site

Cardiovascular disease
View official trial listing →
Not yet recruiting NCT NCT07256171

COAST Study - Cholesterol Optimization After Stroke

Fondazione Policlinico Universitario Agostino Gemelli IRCCS 500 participants Est. completion 2026-12-31

Cardiovascular disease Other conditions: Cerebral Hemorrhage
View official trial listing →
Completed NCT NCT07409636

A Study to Assess the Real-World Effectiveness of Inclisiran and PCSK9 mAbs in Chinese Hypercholesterolemia Adult Patients

Novartis Pharmaceuticals 11991 participants Est. completion 2025-12-22 1 site

Other conditions: Hypercholesterolemia, Mixed Dyslipidemia
View official trial listing →
Completed NCT NCT07421232

A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia

Not yet reported CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. 156 participants Est. completion 2026-02-12 1 site

Other conditions: Hypercholesterolemia and Mixed Hyperlipidemia
View official trial listing →
Not yet recruiting NCT NCT07468500

Real World Adherence of PCSK9 Targeted Therapy

Novartis Pharmaceuticals 3600 participants Est. completion 2026-07-30

Other conditions: Dyslipidemia, Hypercholesterolemia
View official trial listing →
Completed NCT NCT07615166

Low-Density Lipoprotein Cholesterol Reduction With Alirocumab 150 mg Versus Inclisiran in Individuals Initiating Therapy in Routine Clinical Practice

Sanofi 996 participants Est. completion 2026-06-30 1 site

Cardiovascular disease
View official trial listing →
Not yet recruiting NCT NCT07684469

Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia

Not yet reported Novartis Pharmaceuticals 300 participants Est. completion 2028-10-31 Stand-alone

Other conditions: Acute Coronary Syndrome
View official trial listing →
Not yet recruiting NCT NCT07799779

Early Intensive Lipid-Lowering With Inclisiran for Plaque Stabilization in Acute Coronary Syndrome

Not yet reported Seoul National University Bundang Hospital 294 participants Est. completion 2029-09 1 site Stand-alone

Other conditions: Acute Coronary Syndromes (ACS)
View official trial listing →

Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

ClinicalTrials.gov — NCT07102628

Also known as: Inclisiran, LEQVIO

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.